Status:
UNKNOWN
Safety and Immunogenicity of Sars-cov-2 Vaccine in Patients With Rheumatic Diseases
Lead Sponsor:
Yunnan University of Chinese Medicine
Conditions:
Rheumatic Disease
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of this study was to preliminarily evaluate the immunogenicity of sars-cov-2 vaccine in patients with rheumatic diseases. The clinical information collection and blood sample testing of 10...
Detailed Description
Rheumatic diseases (RDS) are a large class of systemic diseases caused by genetic background, environment and physics, infection, metabolism, endocrine, immune response and other reasons, mainly invol...
Eligibility Criteria
Inclusion
- Meet the diagnostic criteria of rheumatic diseases in western medicine;
- 18-70 years old, male or female;
- The patient voluntarily participated in this clinical study, has been informed of relevant matters, and signed the informed consent form
Exclusion
- It does not meet the diagnostic criteria of rheumatic diseases in western medicine
Key Trial Info
Start Date :
January 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05191368
Start Date
January 12 2022
End Date
June 1 2022
Last Update
January 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yunnan University of traditional Chinese Medicine
Kunming, Kunming, China, 650500